StemRIM News

StemRIM to Seek Shareholders' Approval on Capital Stock Reduction

Pharmaceutical firm StemRIM (TYO:4599) will hold an extraordinary general meeting of shareholders on July 24 to vote on the company's proposed capital stock reduction, according to a Wednesday filing.

MT NewswiresMay 9 09:11 ET

StemRIM to Issue Stock Acquisition Rights

StemRIM (TYO:4599) is undertaking a stock option issuance to its external collaborator without costs, to enhance research and development for its Regeneration-Inducing Medicine, according to its filin

MT NewswiresDec 13, 2023 22:08 ET

StemRIM Issues Over 300 Million Yen of Shares as Restricted Stock Compensation

StemRIM (TYO:4599) issued 433,000 shares for 307.4 million yen, or 710 yen apiece, as restricted stock compensation, according to a Wednesday bourse filing. The biotech company issued 393,000 shares t

MT NewswiresDec 6, 2023 19:33 ET

StemRIM Issues 433,000 Shares as Restricted Stock Compensation

StemRIM (TYO:4599) is issuing 433,000 shares for 710 yen per share or 307.43 million yen as restricted stock compensation, according to its filing on Thursday. The biotechnology company has allotted 3

MT NewswiresNov 17, 2023 05:53 ET

StemRIM, Shiseido, Osaka University Extend Skin Aging Research Collaboration

StemRIM (TYO:4599), Shiseido (TYO:4911) and Osaka University have extended their research collaboration, building on data gathered from their research on the aging mechanisms of skin stem cells, a Thu

MT NewswiresNov 17, 2023 02:01 ET

StemRIM Discloses Issuance Details of Stock Options to Directors

StemRIM (TYO:4599) has fixed the exercise price for 990 stock options to be issued to five directors at 79,800 yen per unit or 798 yen per share. In a delayed filing, the biotech venture company said

MT NewswiresSep 20, 2023 01:36 ET

StemRIM FY Parent Net Y168.00M Vs Loss Y1.95B

StemRIM Inc. (4599.TO) Japan Year Ended July 31 PARENT 2023 2022 Revenue Y2.35 bln Y22.00 mln Operating Profit Y142.00 mln (Y1.98 bln)

Dow JonesSep 13, 2023 02:30 ET

StemRIM Sees Parent FY Net Y170.00M

StemRIM Inc. also released the following forecasts: PARENT Year Ending Jul 2023 Revenue Y2.35 bln Operating Profit Y146.00 mln Pretax Profit Y

Dow JonesJun 14, 2023 02:15 ET

StemRIM Bags 450 Million Yen Milestone Payment From Shionogi; Details FY23 Earnings Outlook, Liver Disease Trial Results

05:34 AM EDT, 04/12/2023 (MT Newswires) -- Biotech venture StemRIM (TYO:4599) received a developmental milestone payment of 450 million yen from Shionogi (TYO:4507) following the commencement of a glo

MT NewswiresApr 12, 2023 05:36 ET

StemRIM Sees FY Parent Pretax Y149.00M

PARENT New Forecast For Year to Jul 2023 Revenue Y2.35 bln Operating Profit Y146.00 mln Pretax Profit Y149.00

Dow JonesApr 10, 2023 02:03 ET